News Focus
News Focus
Replies to #74001 on Biotech Values
icon url

DewDiligence

03/15/09 2:44 AM

#74503 RE: DewDiligence #74001

Abbott’s Disappearing Stent Has Visible Promise

http://blogs.wsj.com/health/2009/03/13/abbotts-search-for-a-disappearing-stent

›March 13, 2009, 5:13 PM ET
By Shirley S. Wang

Abbott hit the ground running in the stent market last year, as its Xience V was approved by the FDA in July and became the market leader in a matter of months. (Boston Scientific sells the same stent under the brand name Promus.)

Now comes news about the company’s next-gen effort: a “fully bioabsorbable” stent that’s made of a corn-derived material also used to make dissolvable sutures. The idea is that the stent is inserted to prop open a clogged blood vessel, then gets reabsorbed into the vessel once its no longer needed.

Results from a 30-patient study of the stent were published yesterday in the Lancet, after first being presented at a conference in October 2008.

The study was small, but the data suggested the stent was safe after two years time. There were no cases of blood clots forming inside the stent, a dangerous but rare complication. Also, the stent appeared fully absorbed after two years and the blood vessels seemed able to contract and expand like they would naturally.

This is still early days. It’s not clear how the new stent works in comparison to existing stents since the trial wasn’t designed for a head-to-head comparison. And the company will need lots more data to prove whether the stent is safe and effective. Abbott is hoping for a 2012 launch in Europe and later in the U.S.

Meanwhile, Abbott’s rivals are working on their own new things. Johnson & Johnson, for example, is working on a stent called Nevo that also has a bioabsorbable drug layer, that puts out an anti-clotting drug for about six months, then dissolves leaving a bare metal stent. In 2007, J&J pulled a smiliar product, called CoStar [the product JNJ acquired from Conor in one of its few really bad M&A deals], that was already on the market in some countries. Data showed it wasn’t as good as an existing product.‹
icon url

DewDiligence

03/31/09 3:05 PM

#75327 RE: DewDiligence #74001

ABT ‘Mini’ ReadMeFirst

[Updates:
Xience vs Taxus 3-year data (#msg-36642566);
new section on bioabsorbable stent.]



Finances and outlook
#msg-34983291 4Q08 results
#msg-35632310 Feb 2009 feature in Barron’s


Recent acquisitions
#msg-34762429 Advanced Medical Optics
#msg-34244326 Ibis Biosciences (former ISIS subsidiary)
#msg-34774636 Jan 2009 feature in WSJ


Drug business
#msg-32873850 Humira has become a mega-blockbuster
#msg-26156472 FDA approves Humira for plaque psoriasis
#msg-34203456 FDA approves TriLipix
#msg-26869744 FDA approves Simcor
#msg-29106939 ABT showcases ADHD portfolio


Cholesterol joint venture with AstraZeneca
#msg-11890439 Crestor+TriCor combo pill
#msg-33503193 TriLipix 1-Year combo data
#msg-33263372 Crestor JUPITER data could be game-changer
#msg-28510348 Heart disease: Not about cholesterol?
#msg-30170058 MRK’s Cordaptive delayed until 2013


Xience
#msg-32873087 Xience ramp exceeds forecasts (1)
#msg-32217694 Xience ramp exceeds forecasts (2)
#msg-29264356 Xience blows away Taxus at two years
#msg-36642566 Xience blows away Taxus at three years
#msg-30452522 FDA approves Xience


Bioabsorbable stent
#msg-36509882 Clinical program for bioabsorbable DES
#msg-36292361 WSJ blurb (Mar 2009)
#msg-32869939 Business Week feature (Oct 2008)


Corporate and miscellaneous
#msg-35753218 ABT hikes dividend for 37th consecutive year!
#msg-32844386 New $5B buyback authorization
#msg-31637906 ABT cuts 1,000 jobs
#msg-29708517 Musings on TriCor patent case
#msg-31102936 Musings on Norvir lawsuit